New Horizons in the Management of Alzheimer Disease

Journal of the American Medical Directors Association

Volumn 16, Issue 1, 2015, Pages 1-5

  Morley, John E ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; THIOCTIC ACID;

ALZHEIMER DISEASE; ANDROGEN THERAPY; BEHAVIOR CHANGE; COGNITIVE DEFECT; DELIRIUM; DEMENTIA; EDITORIAL; GERIATRICIAN; HUMAN; LIFESTYLE MODIFICATION; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; NONHUMAN; NURSING HOME PATIENT; PARABIOSIS; PSYCHIATRIST; SLEEP DISORDERED BREATHING; STEM CELL; VIDEOCONFERENCING; BEHAVIOR THERAPY; DISEASE COURSE; EXERCISE; FALLING; FEMALE; LIFESTYLE; MALE; MEDITERRANEAN DIET; NEUROPSYCHOLOGICAL TEST; NURSING HOME; PREVENTION AND CONTROL; QUALITY OF LIFE;

ACCIDENTAL FALLS; ALZHEIMER DISEASE; BEHAVIOR THERAPY; DIET, MEDITERRANEAN; DISEASE PROGRESSION; EXERCISE; FEMALE; HUMANS; LIFE STYLE; MALE; NEUROPSYCHOLOGICAL TESTS; NURSING HOMES; QUALITY OF LIFE;

EID: 84926647994     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2014.10.022     Document Type: Editorial

References (168)

1. Morley J.E. Alzheimer's disease: Future treatments. JAm Med Dir Assoc 2011, 12:1-7.
2. Kerwin D., Claus T.H. Severe Alzheimer's disease: Treatment effects on function and care requirements. JAm Med Dir Assoc 2011, 12:99-104.
3. Fillit H., Hofbauer R.K., Setyawan J., et al. Memantine discontinuation and the health status of nursing home residents with Alzheimer's disease. JAm Med Dir Assoc 2010, 11:636-644.
4. Vann A.S. Current Alzheimer's medications: Effective treatment options, or expensive bottles of hope?. JAm Med Dir Assoc 2013, 14:525-526.
5. Savić A., Mimica N. Two cases of loss of consciousness after long-term memantine treatment. JAm Med Dir Assoc 2013, 14:375-376.
6. Morley J.E. Mild cognitive impairment-a treatable condition. JAm Med Dir Assoc 2014, 15:1-5.
7. Rolland Y., Abellan van Kan G., Vellas B. Physical activity and Alzheimer's disease: From prevention to therapeutic perspectives. JAm Med Dir Assoc 2008, 9:390-405.
8. Morley J.E. The magic of exercise. JAm Med Dir Assoc 2008, 9:375-377.
9. Shah R. The role of nutrition and diet in Alzheimer disease: A systematic review. JAm Med Dir Assoc 2013, 14:398-402.
10. Barton C., Miller B., Yaffe K. Improved evaluation and management of cognitive impairment: Results of a comprehensive intervention in long-term care. JAm Med Dir Assoc 2006, 7:84-89.
11. Nazir A., Mueller C., Perkins A., Arling G. Falls and nursing home residents with cognitive impairment: New insights into quality measures and interventions. JAm Med Dir Assoc 2012, 13:819.e1-819.e6.
12. Cherubini A., Ruggiero C., Dell'Aquila G., et al. Underrecognition and undertreatment of dementia in Italian nursing homes. JAm Med Dir Assoc 2012, 13:759.e7-759.e13.
13. Kaufer D.I., Williams C.S., Braaten A.J., et al. Cognitive screening for dementia and mild cognitive impairment in assisted living: Comparison of 3 tests. JAm Med Dir Assoc 2008, 9:586-593.
14. Cruz-Oliver D.M., Morley J.E. Early detection of cognitive impairment: Do screening tests help?. JAm Med Dir Assoc 2010, 11:1-6.
15. Ferretti M., Seematter-Bagnoud L., Martin E., Büla C.J. New diagnoses of dementia among older patients admitted to postacute care. JAm Med Dir Assoc 2010, 11:371-376.
16. Saliba D., Buchanan J., Edelen M.O., et al. MDS 3.0: Brief interview for mental status. JAm Med Dir Assoc 2012, 13:611-617.
17. Saliba D., Jones M., Streim J., et al. Overview of significant changes in the Minimum Data Set for nursing homes version 3.0. JAm Med Dir Assoc 2012, 13:595-601.
18. Ventura T., De-la-Cámara C., Lopez-Anton R., et al. Usefulness of 2 questions about age and year of birth in the case-finding of dementia. JAm Med Dir Assoc 2013, 14:627.e7-627.e12.
19. Cao L., Hai S., Lin X., et al. Comparison of the Saint Louis University Mental Status Examination, the Mini-Mental State Examination, and the Montreal Cognitive Assessment in detection of cognitive impairment in Chinese elderly from the geriatric department. JAm Med Dir Assoc 2012, 13:626-629.
20. Tariq S.H., Tumosa N., Chibnall J.T., et al. Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder-A pilot study. Am J Geriatr Psychiatry 2006, 14:900-910.
21. Cruz-Oliver D.M., Malmstrom T.K., Roegner M., et al. Cognitive deficit reversal as shown by changes in the Veterans Affairs Saint Louis University Mental Status (SLUMS) examination scores 7.5 years later. JAm Med Dir Assoc 2014, 15:687.e5-687.e10.
22. Cummings-Vaughn L.A., Chavakula N.N., Malmstrom T.K., et al. Veterans Affairs Saint Louis University Mental Status examination compared with the Montreal Cognitive Assessment and the Short Test of Mental Status. JAm Geriatr Soc 2014, 62:1341-1346.
23. Feliciano L., Horning S.M., Klebe K.J., et al. Utility of the SLUMS as a cognitive screening tool among a nonveterans sample of older adults. Am J Geriatr Psychiatry 2013, 21:623-630.
24. Chen M.H., Li C.T., Tsai C.F., et al. Risk of dementia among patients with asthma: A nationwide longitudinal study. JAm Med Dir Assoc 2014, 15:763-767.
25. Ampadu J., Morley J.E. Heart failure and cognitive dysfunction. Int J Cardiol 2015, 178:12-23.
26. Formiga F., Ferrer A., Padrós G., et al. Diabetes mellitus as a risk factor for functional and cognitive decline in very old people: The Octabaix study. JAm Med Dir Assoc 2014, 15:924-928.
27. Sinclair A., Morley J.E. How to manage diabetes mellitus in older persons in the 21st century: Applying these principles to long term diabetes care. JAm Med Dir Assoc 2013, 14:777-780.
28. Sinclair A., Morley J.E., Rodriguez-Mañas L., et al. Diabetes mellitus in older people: Position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. JAm Med Dir Assoc 2012, 13:497-502.
29. Martin-Khan M., Flicker L., Wootton R., et al. The diagnostic accuracy of telegeriatrics for the diagnosis of dementia via video conferencing. JAm Med Dir Assoc 2012, 13:487.e19-487.e24.
30. Flaherty J.H., Morley J.E. Delirium in the nursing home. JAm Med Dir Assoc 2013, 14:632-634.
31. Flaherty J.H., Shay K., Weir C., et al. The development of a mental status vital sign for use across the spectrum of care. JAm Med Dir Assoc 2009, 10:379-380.
32. Flaherty J.H., Rudolph J., Shay K., et al. Delirium is a serious and under-recognized problem: Why assessment of mental status should be the sixth vital sign. JAm Med Dir Assoc 2007, 8:273-275.
33. Morandi A., David D., Fick D.M., et al. Delirium superimposed on dementia strongly predicts worse outcomes in older rehabilitation inpatients. JAm Med Dir Assoc 2014, 15:349-354.
34. Tolson D., Rolland Y., Andrieu S., The International Association of Gerontology and Geriatrics/World Health Organization/Society Française de Gérontologie et de Gériatrie Task Force, et al. International Association of Gerontology and Geriatrics: A global agenda for clinical research and quality of care in nursing homes. JAm Med Dir Assoc 2011, 12:184-189.
35. Morley J.E., Caplan G., Cesari M., et al. International survey of nursing home research priorities. JAm Med Dir Assoc 2014, 15:309-312.
36. Rolland Y., de Souto Barreto P. Research can improve care in the nursing home. JAm Med Dir Assoc 2013, 14:233-235.
37. Morley J.E. Anticholinergic medications and cognition. JAm Med Dir Assoc 2011, 12:543-543.e1.
38. Onder G., Liperoti R., Foebel A., et al. Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: Results from the SHELTER study. JAm Med Dir Assoc 2013, 14:450.e7-450.e12.
39. Fitzgerald S.P., Bean N.G. An analysis of the interactions between individual comorbidities and their treatments-Implications for guidelines and polypharmacy. JAm Med Dir Assoc 2010, 11:475-484.
40. Little M.O., Morley A. Reducing polypharmacy: Evidence from a simple quality improvement initiative. JAm Med Dir Assoc 2013, 14:152-156.
41. Pitkälä K.H., Juola A.L., Kautiainen H., et al. Education to reduce potentially harmful medication use among residents of assisted living facilities: A randomized controlled trial. JAm Med Dir Assoc 2014, 15:892-898.
42. van der Wardt V., Logan P., Controy S., et al. Antihypertensive treatment in people with dementia. JAm Med Dir Assoc 2014, 15:620-629.
43. Peng J., Lu F., Wang Z., et al. Excessive lowering of blood pressure is not beneficial for progression of brain white matter hyperintensive and cognitive impairment in elderly hypertensive patients: 4-year follow-up study. JAm Med Dir Assoc 2014, 15:904-910.
44. Hsiao F.Y., Peng L.N., Lin M.H., Chen L.K. Dose-responsive effect of psychotropic drug use and subsequent dementia: A nationwide propensity score matched case-control study in Taiwan. JAm Med Dir Assoc 2014, 15:509-513.
45. Morley J.E. Antipsychotics and dementia: A time for restraint?. JAm Med Dir Assoc 2012, 13:761-763.
46. Blazer D.G. Antipsychotics and dementia: Where do we go from here?. JAm Med Dir Assoc 2013, 14:307-308.
47. Jennings L., Grossberg G.T. Antipsychotics continue to have a place in the management of difficult behavior problems in patients with dementia. JAm Med Dir Assoc 2013, 14:447-449.
48. Thompson Coon J., Abbott R., Rogers M., et al. Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: A systematic review. JAm Med Dir Assoc 2014, 15:706-718.
49. De Mauleon A., Sourdet S., Renom-Guiteras A., et al. Associated factors with antipsychotic use in long-term institutional care in eight European countries: Results from the RightTimePlaceCare study. JAm Med Dir Assoc 2014, 15:812-818.
50. Foebel A.D., Liperoti R., Onder G., et al. Use of antipsychotic drugs among residents with dementia in European long-term care facilities: Results from the SHELTER study. JAm Med Dir Assoc 2014, 15:911-917.
51. Desai A.K., McFadden S.H. Reducing antipsychotic use in long term care residents: Addressing psychological and spiritual needs of residents with dementia is crucial. JAm Med Dir Assoc 2013, 14:224-225.
52. Hasegawa N., Hashimoto M., Koyama A., et al. Patient-related factors associated with depressive state in caregivers of patients with dementia at home. JAm Med Dir Assoc 2014, 15:371.e15-371.e18.
53. Thakur M., Blazer D.G. Depression in long-term care. JAm Med Dir Assoc 2008, 9:82-87.
54. Morley J.E. Depression in nursing home residents. JAm Med Dir Assoc 2010, 11:301-303.
55. Jupiter T. Cognition and screening for hearing loss in nursing home residents. JAm Med Dir Assoc 2012, 13:744-747.
56. Siraj S. An overview of normal pressure hydrocephalus and its importance: How much do we really know?. JAm Med Dir Assoc 2011, 12:19-21.
57. Udompanich S., Lip G.Y., Apostolakis S., Lane D.A. Atrial fibrillation as a risk factor for cognitive impairment: A semi-systematic review. QJM 2013, 106:795-802.
58. Kalantarian S., Stern T.A., Mansour M., Ruskin J.N. Cognitive impairment associated with atrial fibrillation: A meta-analysis. Ann Intern Med 2013, 158:338-346.
59. Donoghue O.A., Jansen S., Dooley C., et al. Atrial fibrillation is associated with impaired mobility in community-dwelling older adults. JAm Med Dir Assoc 2014, 15:929-933.
60. Vaessen T.J., Overeem S., Sitskoorn M.M. Cognitive complaints in obstructive sleep apnea. Sleep Med Rev 2014 April 2, [Epub ahead of print].
61. Harmand G.-C., Meillon C., Rullier L., et al. Cognitive decline after entering a nursing home: A 22-year follow-up study of institutionalized and noninstitutionalized elderly people. JAm Med Dir Assoc 2014, 15:504-508.
62. Ogama N., Sakurai T., Shimizu A., Toba K. Regional white matter lesions predict falls in patients with amnestic mild cognitive impairment and Alzheimer's disease. JAm Med Dir Assoc 2014, 15:36-41.
63. Shimada H., Makizako H., Doi T., et al. combined prevalence of frailty and mild cognitive impairment in a population of elderly Japanese people. JAm Med Dir Assoc 2013, 14:518-524.
64. Malmstrom T.K., Morley J.E. The frail brain. JAm Med Dir Assoc 2013, 14:453-455.
65. Morley J.E., Vellas B., van Kan G.A., et al. Frailty consensus: A call to action. JAm Med Dir Assoc 2013, 14:392-397.
66. Malmstrom T.K., Morley J.E. Frailty and cognition: Linking two common syndromes in older persons. JNutr Health Aging 2013, 17:723-725.
67. Morley J.E., Malmstrom T.K., Miller D.K. Asimple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. JNutr Health Aging 2012, 16:601-608.
68. Morley J.E. Frailty screening comes of age. JNutr Health Aging 2014, 18:453-454.
69. Woods A.J., Cohen R.A., Pahor M. Cognitive frailty: Frontiers and challenges. JNutr Health Aging 2013, 17:741-743.
70. Buchman A.S., Bennett D.A. Cognitive frailty. JNutr Health Aging 2013, 17:738-739.
71. Erickson K.I., Kramer A.F. Aerobic exercise effects on cognitive and neural plasticity in older adults. Br J Sports Med 2009, 43:22-24.
72. Lam L.C., Chau R.C., Wong B.M., et al. A1-year randomized controlled trial comparing mind body exercise (Tai Chi) with stretching and toning exercise on cognitive function in older Chinese adults at risk of cognitive decline. JAm Med Dir Assoc 2012, 13:568.e15-568.e20.
73. Singh M.A.F., Gates N., Saigal N., et al. The study of mental and resistance training (SMART) study - resistance training and/or cognitive training in mild cognitive impairment: A randomized, double-blind, double-sham controlled trial. JAm Med Dir Assoc 2014, 15:873-880.
74. Aman E., Thomas D.R. Supervised exercise to reduce agitation in severely cognitively impaired persons. JAm Med Dir Assoc 2009, 10:271-276.
75. Caspi E. Time for change: Persons with dementia and "behavioral expressions," not "behavior symptoms.". JAm Med Dir Assoc 2013, 14:768-769.
76. Morley J.E. Dementia-related agitation. JAm Med Dir Assoc 2011, 12:611-612.e2.
77. Yamada M., Arai H., Sonoda T., Aoyama T. Community-based exercise program is cost-effective by preventing care and disability in Japanese frail older adults. JAm Med Dir Assoc 2012, 13:507-511.
78. Singh N.A., Quine S., Clemson L.M., et al. Effects of high-intensity progressive resistance training and multidisciplinary treatment of frailty on mortality and nursing home admissions after hip fracture: A randomized controlled trial. JAm Med Dir Assoc 2012, 13:24-30.
79. Morley J.E. Developing novel therapeutic approaches to frailty. Curr Pharm Des 2009, 15:3384-3395.
80. Brouwer-Brolsma E.M., van de Rest O., Tieland M., et al. Serum 25-hydroxyvitamin D is associated with cognitive executive function in Dutch prefrail and frail elderly: A cross-sectional study exploring the associations of 25-hydroxyvitamin D with glucose metabolism, cognitive performance and depression. JAm Med Dir Assoc 2013, 14:852.e9-852.e17.
81. Granic A., Hill T.R., Kirkwood T.B., et al. Serum 25-hydroxyvitamin D and cognitive decline in the very old: The Newcastle 85+ study. Eur J Neurol 2014 Aug 13, [Epub ahead of print].
82. Brouwer-Brolsma E.M., de Groot L.C. Vitamin D and cognition in older adults: An update of recent findings. Curr Opin Clin Nutr Metab Care 2014, [Epub ahead of print]. PMID:25225898.
83. Morley J.E. Dementia: Does vitamin D modulate cognition?. Nat Rev Neurol 2014, 10:613-614.
84. Singh B., Parsaik A.K., Mielke M.M., et al. Association of Mediterranean diet with mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. JAlzheimers Dis 2014, 39:271-282.
85. Psaltopoulou T., Sergentanis T.N., Panagiotakos D.B., et al. Mediterranean diet, stroke, cognitive impairment, and depression: A meta-analysis. Ann Neurol 2013, 74:580-591.
86. Farr S.A., Price T.O., Dominguez L.J., et al. Extra virgin olive oil improves learning and memory in SAMP8 mice. JAlzheimers Dis 2012, 28:81-92.
87. Martinez-Lapiscina E.H., Clavero P., Toledo E., et al. Virgin olive oil supplementation and long-term cognition: The PREDIMED-NAVARRA randomized trial. JNutr Health Aging 2013, 17:544-552.
88. León-Muñoz L.M., Guallar-Castillón P., López-García E., Rodríguez-Artalejo F. Mediterranean diet and risk of frailty in community-dwelling older adults. JAm Med Dir Assoc 2014, 15:899-903.
89. Morris M.C., Evans D.A., Tangney C.C., et al. Fish consumption and cognitive decline with age in a large community study. Arch Neurol 2005, 62:1849-1853.
90. Qin B., Plassman B., Edwards L.J., et al. Fish intake is associated with slower cognitive decline in Chinese older adults. JNutr 2014, 144:1579-1585.
91. Petursdottir A.L., Farr S.A., Morley J.E., et al. Effect of dietary n-3 polyunsaturated fatty acids on brain lipid fatty acid composition, learning ability, and memory of senescence-accelerated mouse. JGerontol A Biol Sci Med Sci 2008, 63:1153-1160.
92. Issa A.M., Mojica W.A., Morton S.C., et al. The efficacy of omega-3 fatty acids on cognitive function in aging and dementia: A systematic review. Dement Geriatr Cogn Disord 2006, 21:88-96.
93. Carrié I., Abellan van Kan G., Rolland Y., et al. PUFA for prevention and treatment of dementia?. Curr Pharm Des 2009, 15:4173-4185.
94. Garcia-Ptacek S., Kareholt I., Farahmand B., et al. Body-mass index and mortality in incident dementia: A cohort study on 11,398 patients from SveDem, the Swedish Dementia Registry. JAm Med Dir Assoc 2014, 15:447.e1-447.e7.
95. Morley J.E. Anorexia of aging: A true geriatric syndrome. JNutr Health Aging 2012, 16:422-425.
96. Tamura B.K., Bell C.L., Masaki K.H., Amella E.J. Factors associated with weight loss, low BMI, and malnutrition among nursing home patients: A systematic review of the literature. JAm Med Dir Assoc 2013, 14:649-655.
97. Soenen S., Chapman I.M. Body weight, anorexia, and undernutrition in older people. JAm Med Dir Assoc 2013, 14:642-648.
98. Stange I., Bartram M., Liao Y., et al. Effects of a low-volume, nutrient- and energy-dense oral nutritional supplement on nutritional and functional status: A randomized, controlled trial in nursing home residents. JAm Med Dir Assoc 2013, 14:628.e1-628.e8.
99. Ritchie C.W., Bajwa J., Coleman G., et al. Souvenaid®: A new approach to management of early Alzheimer's disease. JNutr Health Aging 2014, 18:291-299.
100. Kamphuis P.J., Verhey F.R., Olde Rikkert M.G., et al. Efficacy of a medical food on cognition in Alzheimer's disease: Results from secondary analyses of a randomized, controlled trial. JNutr Health Aging 2011, 15:720-724.
101. Kamphius P.J., Verhey F.R., Olde Rikkert M.G., et al. Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer's disease: Secondary analyses from a randomized, controlled trial. JNutr Health Aging 2011, 15:672-676.
102. Yamaguchi H., Maki Y., Takahashi K. Rehabilitation for dementia using enjoyable video-sports games. Int Psychogeriatr 2011, 23:674-676.
103. Cherniack E.P. Not just fun and games: Applications of virtual reality in the identification and rehabilitation of cognitive disorders of the elderly. Disabil Rehabil Assist Technol 2011, 6:283-289.
104. Anderson K., Grossberg G.T. Brain games to slow cognitive decline in Alzheimer's disease. JAm Med Dir Assoc 2014, 15:536-537.
105. Van Bogaert P., Van Grinsven R., Tolson D., et al. Effects of SolCos model-based individual reminiscence on older adults with mild to moderate dementia due to Alzheimer disease: A pilot study. JAm Med Dir Assoc 2013, 14:528.e9-528.e13.
106. Wingbermuehle C., Bryer D., Berg-Weger M., et al. Baseball reminiscence league: A model for supporting persons with dementia. JAm Med Dir Assoc 2014, 15:85-89.
107. Robinson H., MacDonald B., Kerse N., Broadbent E. The psychosocial effects of a companion robot: A randomized controlled trial. JAm Med Dir Assoc 2013, 14:661-667.
108. Bemelmans R., Gelderblom G.J., Jonker P., de Witte L. Socially assistive robots in elderly care: A systematic review into effects and effectiveness. JAm Med Dir Assoc 2012, 13:114-120.e1.
109. Banks M.R., Willoughby L.M., Banks W.A. Animal-assisted therapy and loneliness in nursing homes: Use of robotic versus living dogs. JAm Med Dir Assoc 2008, 9:173-177.
110. Banks W.A. Artificial emotions: Robots caring for the elderly. JAm Med Dir Assoc 2013, 14:635-636.
111. Li H.-C., Wang H.-H., Chou F.-H., Chen K.-M. The effect of music therapy on cognitive functioning among older adults: A systematic review and meta-analysis. JAm Med Dir Assoc 2015, 16:71-77.
112. Low L.F., Goodenough B., Fletcher J., et al. The effects of humor therapy on nursing home residents measured using observational methods: The SMILE cluster randomized trial. JAm Med Dir Assoc 2014, 15:564-569.
113. Whear R., Coon J.T., Bethel A., et al. What is the impact of using outdoor spaces such as gardens on the physical and mental well-being of those with dementia? A systematic review of quantitative and qualitative evidence. JAm Med Dir Assoc 2014, 15:697-705.
114. Dementia care: What in the world is a dementia village? Available at: . Accessed October 28,2014. http://www.alzheimers.net/2013-08-07/dementia-village.
115. Soto M.E., Andrieu S., Villars H., et al. Improving care of older adults with dementia: Description of 6299 hospitalizations over 11 years in a special acute care unit. JAm Med Dir Assoc 2005, 6:276-280.
116. Bass E., Putney K., Alvear M. Economic aspects of dementia special care units in Veterans Affairs nursing homes. JAm Med Dir Assoc 2005, 6:276-280.
117. Coleman M.T., Looney S., O'Brien J., et al. The Eden alternative: Findings after 1 year of implementation. JGerontol A Biol Sci Med Sci 2002, 57:M422-M427.
118. Rosher R.B., Robinson S. Impact of the Eden Alternative on family satisfaction. JAm Med Dir Assoc 2005, 6:189-193.
119. Morley J.E., Cruz-Oliver D.M. Cognitive stimulation therapy. JAm Med Dir Assoc 2014, 15:689-691.
120. Orrell M., Aguirre E., Spector A., et al. Maintenance cognitive stimulation therapy for dementia: Single-blind, multicenter, pragmatic randomised controlled trial. Br J Psychiatry 2014, 204:454-461.
121. Orrell M. The new generation of psychosocial interventions for dementia care. Br J Psychiatry 2012, 201:342-343.
122. Aguirre E., Woods R.T., Spector A., Orrell M. Cognitive stimulation for dementia: A systematic review of the evidence of effectiveness from randomised controlled trials. Ageing Res Rev 2013, 12:253-262.
123. Loraine J., Taylor S., McAllister M. Cognitive and physical stimulation therapy. JAm Med Dir Assoc 2014, 15:140-141.
124. Kawashima R., Lewis Hiller D., Sereda S.L., et al. SAIDO learning as a cognitive intervention for dementia care: A preliminary study. JAm Med Dir Assoc 2015, 16:56-62.
125. D'Amico F., Rehill A., Knapp M., et al. Maintenance cognitive stimulation therapy: An economic evaluation within a randomized controlled trial. JAm Med Dir Assoc 2015, 16:63-70.
126. Kivipelto M., Solomon A., Ahtiluoto S., et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): Study design and progress. Alzheimers Dement 2013, 9:657-665.
127. Verghese J., Lipton R.B., Katz M.J., et al. Leisure activities and the risk of dementia in the elderly. NEngl J Med 2003, 348:2508-2516.
128. Tan C.C., Yu J.T., Wang H.F., et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. JAlzheimers Dis 2014, 41:615-631.
129. Bond M., Rogers G., Peters J., et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): A systematic review and economic model. Health Technol Assess 2012, 16:1-470.
130. Prins N.D., Scheltens P. Treating Alzheimer's disease with monoclonal antibodies: Current status and outlook for the future. Alzheimers Res Ther 2013, 5:56.
131. Flood J.F., Roberts E., Sherman M.A., et al. Topography of a binding site for small amnestic peptides deduced from structure-activity studies: Relation to amnestic effect of amyloid beta protein. Proc Natl Acad Sci U S A 1994, 91:380-384.
132. Flood J.F., Morley J.E., Roberts E. An amyloid beta-protein fragment, a beta [12-28], equipotently impairs post-training memory processing when injected into different limbic system structures. Brain Res 1994, 663:271-276.
133. Morley J.E., Farr S.A. Hormesis and amyloid-β protein: Physiology or pathology?. JAlzheimers Dis 2012, 29:487-492.
134. Morley J.E., Farr S.A., Banks W.A., et al. Aphysiological role for amyloid-beta protein: Enhancement of learning and memory. JAlzheimers Dis 2010, 19:441-449.
135. Flood J.F., Morley J.E. Learning and memory in the SAMP8 mouse. Neurosci Biobehav Rev 1998, 22:1-20.
136. Morley J.E., Farr S.A., Kumar V.B., Armbrecht H.J. The SAMP8 mouse: A model to develop therapeutic interventions for Alzheimer's disease. Curr Pharm Des 2012, 18:1123-1130.
137. Morley J.E., Armbrecht H.J., Farr S.A., Kumar V.B. The senescence accelerated mouse (SAMP8) as a model for oxidative stress and Alzheimer's disease. Biochim Biophys Acta 2012, 1822:650-656.
138. Flood J.F., Morley J.E. Age-related-changes in footshock avoidance acquisition and retention in senescence accelerated mouse (SAM). Neurobiol Aging 1993, 14:153-157.
139. Farr S.A., Banks W.A., Uezu K., et al. Antibody to beta-amyloid protein increases acetylcholine in the hippocampus of 12 month SAMP8 male mice. Life Sci 2003, 73:555-562.
140. Banks W.A., Farr S.A., Morley J.E., et al. Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: An age-related selective uptake with reversal of learning impairment. Exp Neurol 2007, 206:248-256.
141. Morley J.E., Farr S.A., Flood J.F. Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice. Neurobiol Learn Mem 2002, 78:125-138.
142. Kumar V.B., Farr S.A., Flood J.F., et al. Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides 2000, 21:1769-1775.
143. Farr S.A., Erickson M.A., Niehoff M.L., et al. Central and peripheral administration of antisense oligonucleotide targeting amyloid-β protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (AβPPswe) mice. JAlzheimers Dis 2014, 40:1005-1016.
144. Poon H.F., Farr S.A., Banks W.A., et al. Proteomic identification of less oxidized brain proteins in aged senescence-accelerated mice following administration of antisense oligonucleotide directed at the Abeta region of amyloid precursor protein. Brain Res Mol Brain Res 2005, 138:8-16.
145. Farr S.A., Poon H.F., Dogrukol-Ak D., et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. JNeurochem 2003, 84:1173-1183.
146. Banks W.A., Farr S.A., Butt W., et al. Delivery across the blood-brain barrier of antisense directed against amyloid beta: Reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. JPharmacol Exp Ther 2001, 297:1113-1121.
147. Fiorini A., Sultana R., Förster S., et al. Antisense directed against PS-1 gene decreases brain oxidative markers in aged senescence accelerated mice (SAMP8) and reverses learning and memory impairment: A proteomics study. Free Radic Biol Med 2013, 65:1-14.
148. Farr S.A., Ripley J.L., Sultana R., et al. Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med 2014, 67:387-395.
149. DeVos S.L., Goncharoff D.K., Chen G., et al. Antisense reduction of tau in adult mice protects against seizures. JNeurosci 2013, 33:12887-12897.
150. Winer L., Srinivasan D., Chun S., et al. SOD1 in cerebral spinal fluid as a pharmacodynamics marker for antisense oligonucleotide therapy. JAMA Neurol 2013, 70:201-207.
151. Poon H.F., Farr S.A., Thongboonkerd V., et al. Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: Implications for aging and age-related neurodegenerative disorders. Neurochem Int 2005, 46:159-168.
152. Hager K., Kenklies M., McAfoose J., et al. Alpha-lipoic acid as a new treatment option for Alzheimer's disease-A 48 months follow-up analysis. JNeural Transm Suppl 2007, 72:189-193.
153. Farr S.A., Price T.O., Banks W.A., et al. Effect of alpha-lipoic acid on memory, oxidation, and lifespan in SAMP8 mice. JAlzheimers Dis 2012, 32:447-455.
154. Choi S.S., Lee S.R., Kim S.U., Lee H.J. Alzheimer's disease and stem cell therapy. Exp Neurobiol 2014, 23:45-52.
155. Fan X., Sun D., Tang X., et al. Stem-cell challenges in the treatment of Alzheimer's disease: A long way from bench to bedside. Med Res Rev 2014, 34:957-978.
156. Tuszynski M.H., Thal L., Pay M., et al. Aphase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005, 11:551-555.
157. Thomson H. Young blood to be used in ultimate rejuvenation trial. Available at: . Accessed November 25, 2014. http://www.newscientist.com/aticle/mg22329831.400-young-blood-to-be-used-in-ultimate-rejuvenation-trial.html#.VHTsD9LF-xW.
158. Katsimpardi L., Litterman N.K., Schein P.A., et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 2014, 344:630-634.
159. Craft S., Baker L.D., Montine T.J., et al. Intranasal insulin therapy for Alzheimer's disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol 2012, 69:29-38.
160. During M.J., Cao L., Zuzga D.S., et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9:1173-1179.
161. Read S., Wu P., Biscow M. Sustained 4-year cognitive and functional response in early Alzheimer's disease with pioglitazone. JAm Geriatr Soc 2014, 62:584-586.
162. Ng T.P., Feng L., Yap K.B., et al. Long-term metformin usage and cognitive function among older adults with diabetes. JAlzheimers Dis 2014, 41:61-68.
163. Chu L.W., Tam S., Lee P.W., et al. Bioavailable testosterone is associated with a reduced risk of amnestic mild cognitive impairment in older men. Clin Endocrinol (Oxf) 2008, 68:589-598.
164. Chu L.W., Tam S., Wong R.L., et al. Bioavailable testosterone predicts a lower risk of Alzheimer's disease in older men. JAlzheimers Dis 2010, 21:1335-1345.
165. Morley J.E., Kaiser F., Raum W.J., et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: Progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci U S A 1997, 94:7537-7542.
166. Farr J.F., Farr S.A., Kaiser F.E., et al. Age-related decrease of plasma testosterone in SAMP8 mice: Replacement improves age-related impairment of learning and memory. Physiol Behav 1995, 57:669-673.
167. Cherrier M.M. Testosterone effects on cognition in health and disease. Front Horm Res 2009, 37:150-162.
168. Cherrier M.M., Matsumoto A.M., Amory J.K., et al. Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in health older men. Psychoneuroendocrinology 2007, 32:72-79.